In support of this notion, previous clinical studies examining the effectiveness of the monoclonal antibody against the MM PC cell-surface protein SLAMF7 (elotuzumab) showed limited clinical activity as a single agent, but was able to limit MM disease progression and improve overall survival when combined with frontline MM therapies [48]. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.